Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients

Gautam Baheti, Jennifer J. Kiser, Peter L. Havens, Courtney V. Fletcher

Research output: Contribution to journalArticlepeer-review

66 Scopus citations


The relationships among the dose of tenofovir disoproxil fumarate (TDF), tenofovir (TFV) plasma concentrations, and intracellular TFV diphosphate (TFV-DP) concentrations are poorly understood. Our objective was to characterize TFV and TFV-DP relationships. Data were pooled from two studies in HIV-infected persons (n = 55) on stable antiretroviral therapy. TFV and TFV-DP were measured with validated liquid chromatography/tandem mass spectrometry (LC/MS/MS) methods. Nonlinear mixed effects modeling (NONMEM 7) was used to develop the population model and explore the influence of covariates on TFV. A sequential analysis approach was utilized. A two-compartment model with first-order absorption best described TFV PK (FOCEI). An indirect stimulation of response model best described TFV-DP, where formation of TFV-DP was driven by plasma TFV concentration. Final plasma population estimates were as follows: absorption rate constant, 1.03 h -1; apparent clearance (CL/F), 42 liters/h (33.5% interindividual variability [IIV]); intercompartment clearance, 181 liters/h; apparent central distribution volume (Vc/F), 273 liters (64.8% IIV); and apparent peripheral distribution volume (Vp/F), 440 liters (46.5% IIV). Creatinine clearance was the most significant covariate on CL/F and Vc/F. The correlation between CL/F and Vc/F was 0.553. The indirect response model for TFV-DP resulted in estimates of the maximal intracellular concentration (E max), the TFV concentration producing 50% of E max (EC 50), and the intracellular elimination rate constant (k out) of 300 fmol/10 6 cells (82% IIV), 100 ng/ml (106% IIV), and 0.008 h -1, respectively. The estimated k out gave an 87-h TFV-DP half-life. A predictive check assessment indicated satisfactory model performance. This model links formation of TFV-DP with plasma TFV concentrations and should facilitate more informed investigations of TFV clinical pharmacology.

Original languageEnglish (US)
Pages (from-to)5294-5299
Number of pages6
JournalAntimicrobial Agents and Chemotherapy
Issue number11
StatePublished - Nov 2011

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases


Dive into the research topics of 'Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients'. Together they form a unique fingerprint.

Cite this